Cargando…
The TH1902 Docetaxel Peptide-Drug Conjugate Inhibits Xenografts Growth of Human SORT1-Positive Ovarian and Triple-Negative Breast Cancer Stem-like Cells
Background: Breast and ovarian cancer stem cells (CSC) can contribute to the invasive and chemoresistance phenotype of tumors. TH1902, a newly developed sortilin (SORT1)-targeted peptide-docetaxel conjugate is currently in phase-1 clinical trial. Whether TH1902 impacts the chemoresistance phenotype...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503230/ https://www.ncbi.nlm.nih.gov/pubmed/36145658 http://dx.doi.org/10.3390/pharmaceutics14091910 |
_version_ | 1784795910759251968 |
---|---|
author | Demeule, Michel Charfi, Cyndia Currie, Jean-Christophe Zgheib, Alain Danalache, Bogdan Alexandru Béliveau, Richard Marsolais, Christian Annabi, Borhane |
author_facet | Demeule, Michel Charfi, Cyndia Currie, Jean-Christophe Zgheib, Alain Danalache, Bogdan Alexandru Béliveau, Richard Marsolais, Christian Annabi, Borhane |
author_sort | Demeule, Michel |
collection | PubMed |
description | Background: Breast and ovarian cancer stem cells (CSC) can contribute to the invasive and chemoresistance phenotype of tumors. TH1902, a newly developed sortilin (SORT1)-targeted peptide-docetaxel conjugate is currently in phase-1 clinical trial. Whether TH1902 impacts the chemoresistance phenotype of human triple-negative breast CSC (hTNBCSC) and ovarian CSC (hOvCSC) is unknown. Methods and Results: Immunophenotyping of hTNBCSC and hOvCSC was performed by flow cytometry and confirmed the expression of SORT1, and of CSC markers CD133, NANOG, and SOX2. Western blotting demonstrated the expression of the drug efflux pumps from the P-gp family members, ABCB1 and ABCB5. The cellular uptake of the fluorescent Alexa(488)-peptide from TH1902 was inhibited upon siRNA-mediated repression of SORT1 or upon competition with SORT1 ligands. In contrast to docetaxel, TH1902 inhibited in vitro migration, induced cell apoptosis and lead to G2/M cell cycle arrest of the hTNBCSC. These events were unaffected by the presence of the P-gp inhibitors cyclosporine A or PSC-833. In vivo, using immunosuppressed nude mice xenografts, TH1902 significantly inhibited the growth of hTNBCSC and hOvCSC xenografts (~80% vs. ~35% for docetaxel) when administered weekly as intravenous bolus for three cycles at 15 mg/kg, a dose equivalent to the maximal tolerated dose of docetaxel. Therapeutic efficacy was further observed when carboplatin was combined to TH1902. Conclusions: Overall, TH1902 exerts a superior anticancer activity than the unconjugated docetaxel, in part, by circumventing the CSC drug resistance phenotype that could potentially reduce cancer recurrence attributable to CSC. |
format | Online Article Text |
id | pubmed-9503230 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95032302022-09-24 The TH1902 Docetaxel Peptide-Drug Conjugate Inhibits Xenografts Growth of Human SORT1-Positive Ovarian and Triple-Negative Breast Cancer Stem-like Cells Demeule, Michel Charfi, Cyndia Currie, Jean-Christophe Zgheib, Alain Danalache, Bogdan Alexandru Béliveau, Richard Marsolais, Christian Annabi, Borhane Pharmaceutics Article Background: Breast and ovarian cancer stem cells (CSC) can contribute to the invasive and chemoresistance phenotype of tumors. TH1902, a newly developed sortilin (SORT1)-targeted peptide-docetaxel conjugate is currently in phase-1 clinical trial. Whether TH1902 impacts the chemoresistance phenotype of human triple-negative breast CSC (hTNBCSC) and ovarian CSC (hOvCSC) is unknown. Methods and Results: Immunophenotyping of hTNBCSC and hOvCSC was performed by flow cytometry and confirmed the expression of SORT1, and of CSC markers CD133, NANOG, and SOX2. Western blotting demonstrated the expression of the drug efflux pumps from the P-gp family members, ABCB1 and ABCB5. The cellular uptake of the fluorescent Alexa(488)-peptide from TH1902 was inhibited upon siRNA-mediated repression of SORT1 or upon competition with SORT1 ligands. In contrast to docetaxel, TH1902 inhibited in vitro migration, induced cell apoptosis and lead to G2/M cell cycle arrest of the hTNBCSC. These events were unaffected by the presence of the P-gp inhibitors cyclosporine A or PSC-833. In vivo, using immunosuppressed nude mice xenografts, TH1902 significantly inhibited the growth of hTNBCSC and hOvCSC xenografts (~80% vs. ~35% for docetaxel) when administered weekly as intravenous bolus for three cycles at 15 mg/kg, a dose equivalent to the maximal tolerated dose of docetaxel. Therapeutic efficacy was further observed when carboplatin was combined to TH1902. Conclusions: Overall, TH1902 exerts a superior anticancer activity than the unconjugated docetaxel, in part, by circumventing the CSC drug resistance phenotype that could potentially reduce cancer recurrence attributable to CSC. MDPI 2022-09-09 /pmc/articles/PMC9503230/ /pubmed/36145658 http://dx.doi.org/10.3390/pharmaceutics14091910 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Demeule, Michel Charfi, Cyndia Currie, Jean-Christophe Zgheib, Alain Danalache, Bogdan Alexandru Béliveau, Richard Marsolais, Christian Annabi, Borhane The TH1902 Docetaxel Peptide-Drug Conjugate Inhibits Xenografts Growth of Human SORT1-Positive Ovarian and Triple-Negative Breast Cancer Stem-like Cells |
title | The TH1902 Docetaxel Peptide-Drug Conjugate Inhibits Xenografts Growth of Human SORT1-Positive Ovarian and Triple-Negative Breast Cancer Stem-like Cells |
title_full | The TH1902 Docetaxel Peptide-Drug Conjugate Inhibits Xenografts Growth of Human SORT1-Positive Ovarian and Triple-Negative Breast Cancer Stem-like Cells |
title_fullStr | The TH1902 Docetaxel Peptide-Drug Conjugate Inhibits Xenografts Growth of Human SORT1-Positive Ovarian and Triple-Negative Breast Cancer Stem-like Cells |
title_full_unstemmed | The TH1902 Docetaxel Peptide-Drug Conjugate Inhibits Xenografts Growth of Human SORT1-Positive Ovarian and Triple-Negative Breast Cancer Stem-like Cells |
title_short | The TH1902 Docetaxel Peptide-Drug Conjugate Inhibits Xenografts Growth of Human SORT1-Positive Ovarian and Triple-Negative Breast Cancer Stem-like Cells |
title_sort | th1902 docetaxel peptide-drug conjugate inhibits xenografts growth of human sort1-positive ovarian and triple-negative breast cancer stem-like cells |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503230/ https://www.ncbi.nlm.nih.gov/pubmed/36145658 http://dx.doi.org/10.3390/pharmaceutics14091910 |
work_keys_str_mv | AT demeulemichel theth1902docetaxelpeptidedrugconjugateinhibitsxenograftsgrowthofhumansort1positiveovarianandtriplenegativebreastcancerstemlikecells AT charficyndia theth1902docetaxelpeptidedrugconjugateinhibitsxenograftsgrowthofhumansort1positiveovarianandtriplenegativebreastcancerstemlikecells AT curriejeanchristophe theth1902docetaxelpeptidedrugconjugateinhibitsxenograftsgrowthofhumansort1positiveovarianandtriplenegativebreastcancerstemlikecells AT zgheibalain theth1902docetaxelpeptidedrugconjugateinhibitsxenograftsgrowthofhumansort1positiveovarianandtriplenegativebreastcancerstemlikecells AT danalachebogdanalexandru theth1902docetaxelpeptidedrugconjugateinhibitsxenograftsgrowthofhumansort1positiveovarianandtriplenegativebreastcancerstemlikecells AT beliveaurichard theth1902docetaxelpeptidedrugconjugateinhibitsxenograftsgrowthofhumansort1positiveovarianandtriplenegativebreastcancerstemlikecells AT marsolaischristian theth1902docetaxelpeptidedrugconjugateinhibitsxenograftsgrowthofhumansort1positiveovarianandtriplenegativebreastcancerstemlikecells AT annabiborhane theth1902docetaxelpeptidedrugconjugateinhibitsxenograftsgrowthofhumansort1positiveovarianandtriplenegativebreastcancerstemlikecells AT demeulemichel th1902docetaxelpeptidedrugconjugateinhibitsxenograftsgrowthofhumansort1positiveovarianandtriplenegativebreastcancerstemlikecells AT charficyndia th1902docetaxelpeptidedrugconjugateinhibitsxenograftsgrowthofhumansort1positiveovarianandtriplenegativebreastcancerstemlikecells AT curriejeanchristophe th1902docetaxelpeptidedrugconjugateinhibitsxenograftsgrowthofhumansort1positiveovarianandtriplenegativebreastcancerstemlikecells AT zgheibalain th1902docetaxelpeptidedrugconjugateinhibitsxenograftsgrowthofhumansort1positiveovarianandtriplenegativebreastcancerstemlikecells AT danalachebogdanalexandru th1902docetaxelpeptidedrugconjugateinhibitsxenograftsgrowthofhumansort1positiveovarianandtriplenegativebreastcancerstemlikecells AT beliveaurichard th1902docetaxelpeptidedrugconjugateinhibitsxenograftsgrowthofhumansort1positiveovarianandtriplenegativebreastcancerstemlikecells AT marsolaischristian th1902docetaxelpeptidedrugconjugateinhibitsxenograftsgrowthofhumansort1positiveovarianandtriplenegativebreastcancerstemlikecells AT annabiborhane th1902docetaxelpeptidedrugconjugateinhibitsxenograftsgrowthofhumansort1positiveovarianandtriplenegativebreastcancerstemlikecells |